NO20042055L - Tymosinalfa 1-peptid/polymerkonjugater - Google Patents

Tymosinalfa 1-peptid/polymerkonjugater

Info

Publication number
NO20042055L
NO20042055L NO20042055A NO20042055A NO20042055L NO 20042055 L NO20042055 L NO 20042055L NO 20042055 A NO20042055 A NO 20042055A NO 20042055 A NO20042055 A NO 20042055A NO 20042055 L NO20042055 L NO 20042055L
Authority
NO
Norway
Prior art keywords
peptide
alpha
thymosinal
polymer conjugates
administered
Prior art date
Application number
NO20042055A
Other languages
English (en)
Norwegian (no)
Inventor
Alfred R Rudolph
Cynthia W Tuthill
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of NO20042055L publication Critical patent/NO20042055L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO20042055A 2001-11-01 2004-05-18 Tymosinalfa 1-peptid/polymerkonjugater NO20042055L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33087001P 2001-11-01 2001-11-01
PCT/US2002/035094 WO2003037272A2 (en) 2001-11-01 2002-11-01 Thymosin alpha 1 peptide/polymer conjugates

Publications (1)

Publication Number Publication Date
NO20042055L true NO20042055L (no) 2004-05-18

Family

ID=23291654

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042055A NO20042055L (no) 2001-11-01 2004-05-18 Tymosinalfa 1-peptid/polymerkonjugater

Country Status (17)

Country Link
US (2) US7297676B2 (de)
EP (1) EP1455766B1 (de)
JP (1) JP2005511553A (de)
KR (1) KR20050042230A (de)
CN (1) CN100536910C (de)
AT (1) ATE549036T1 (de)
AU (1) AU2002353964B2 (de)
BR (1) BR0213821A (de)
CA (1) CA2465874A1 (de)
EA (1) EA008703B1 (de)
IL (1) IL161670A0 (de)
MX (1) MXPA04004188A (de)
NO (1) NO20042055L (de)
NZ (1) NZ532719A (de)
PL (1) PL373795A1 (de)
UA (1) UA78726C2 (de)
WO (1) WO2003037272A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050086819A (ko) 2002-11-25 2005-08-30 시클론 파마수티컬 인코포레이티드 알파 티모신을 사용한 방사능 손상에 대한 보호방법
JP2007530440A (ja) * 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ(エチレングリコール)修飾化合物およびその用途
JP5087274B2 (ja) * 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
CN100355786C (zh) * 2004-04-28 2007-12-19 江苏豪森药业股份有限公司 聚乙二醇修饰的胸腺肽1衍生物
CN1314708C (zh) * 2004-05-24 2007-05-09 华东师范大学 一种人α1-胸腺肽的复合物及其制备方法
CN100500844C (zh) * 2005-03-07 2009-06-17 上海普洛康裕药物研究院有限公司 重组胸腺素α1在大肠杆菌中的高分泌表达和分离纯化
CN100577685C (zh) 2005-11-10 2010-01-06 中国人民解放军军事医学科学院毒物药物研究所 长效胸腺素α1的聚乙二醇化修饰物
CN101062950B (zh) * 2006-04-25 2010-04-21 江苏豪森药业股份有限公司 聚乙二醇修饰的胸腺肽1衍生物
US8017129B2 (en) * 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
EP2350118B1 (de) * 2008-09-19 2016-03-30 Nektar Therapeutics Kohlenhydratbasisierte polymere zur wirkstoffabgabe und konjugate davon
US20110171162A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
HUE054875T2 (hu) 2012-05-18 2021-10-28 Replicor Inc Oligonukleotid kelátkomplex-polipeptid készítmények és eljárások
CN122277697A (zh) * 2026-04-09 2026-06-26 中国人民解放军总医院第二医学中心 一种新型磁共振造影剂及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5308833A (en) * 1992-02-06 1994-05-03 Sciclone Pharmaceuticals Method for treating hepatitis B carriers with minimal disease
AU5006993A (en) * 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
CN1094310A (zh) 1992-12-15 1994-11-02 托马斯·C·梅里根 人体免疫缺陷性病毒感染用组合式化学疗法
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
DK1007082T3 (da) * 1997-01-15 2007-02-19 Phoenix Pharmacologics Inc Modificeret tumor nekrose faktor
JP2002527059A (ja) * 1998-10-13 2002-08-27 ノボザイムス アクティーゼルスカブ 低められた免疫応答を有する修飾されたポリペプチド
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
WO2001074399A1 (en) * 2000-03-30 2001-10-11 Ajinomoto Co., Inc. Drugs retained in target tissue over long time
EP2316490A3 (de) * 2000-10-31 2012-02-01 PR Pharmaceuticals, Inc. Verfahren und Formulierungen zur verbesserten Abgabe von bioaktiven Molekülen
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins

Also Published As

Publication number Publication date
PL373795A1 (en) 2005-09-19
US20040248792A1 (en) 2004-12-09
EA200400592A1 (ru) 2004-12-30
US7297676B2 (en) 2007-11-20
BR0213821A (pt) 2004-08-31
UA78726C2 (en) 2007-04-25
IL161670A0 (en) 2004-09-27
EP1455766B1 (de) 2012-03-14
US20080152668A1 (en) 2008-06-26
WO2003037272A3 (en) 2003-11-20
CN100536910C (zh) 2009-09-09
AU2002353964B2 (en) 2006-08-03
NZ532719A (en) 2005-11-25
MXPA04004188A (es) 2004-07-08
ATE549036T1 (de) 2012-03-15
CA2465874A1 (en) 2003-05-08
EP1455766A4 (de) 2008-11-05
EP1455766A2 (de) 2004-09-15
CN1582162A (zh) 2005-02-16
EA008703B1 (ru) 2007-06-29
JP2005511553A (ja) 2005-04-28
KR20050042230A (ko) 2005-05-06
WO2003037272A2 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
KR100345214B1 (ko) 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
ATE549036T1 (de) Thymosin-alpha-1-peptid/polymer-konjugate
MXPA05005330A (es) Composiciones y formulaciones de gastrina, y metodos de uso y preparacion.
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
AR008378A1 (es) Conjudados de interferon
TR200002299T2 (tr) Epotilon kompozisyonları.
AU1385699A (en) Novel conjugates of rgd-containing peptides and endogenous carriers
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
GB2355009A (en) Peptides conjugated to bile acids/salts
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
DK1173476T3 (da) Funktionelle sojabönneproteiner
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
EA200301295A1 (ru) Полипептид, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
DE60036199D1 (de) Proteaseresistente flint-analoge
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
BR0207017A (pt) Fator de crescimento ceratinócito modificado (kgf) com imunogenicidade reduzida
IL117564A0 (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
RU2350351C2 (ru) Композиции и лекарственные формы на основе гастрина, методы применения и получения
Mezö et al. Properties of GnRH conjugates in vivo
Toth et al. Liposaccharides: Utilisation for Peptide Delivery and for Enhancing Synthetic Peptide Immunogenicity

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application